Equities analysts expect Aimmune Therapeutics, Inc. (NASDAQ:AIMT) to report ($0.64) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Aimmune Therapeutics’ earnings. The highest EPS estimate is ($0.60) and the lowest is ($0.68). Aimmune Therapeutics reported earnings of ($0.43) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 48.8%. The firm is expected to issue its next earnings results on Wednesday, August 9th.

On average, analysts expect that Aimmune Therapeutics will report full-year earnings of ($2.58) per share for the current year, with EPS estimates ranging from ($2.69) to ($2.44). For the next fiscal year, analysts anticipate that the company will report earnings of ($3.24) per share, with EPS estimates ranging from ($3.38) to ($3.02). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Aimmune Therapeutics.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings results on Monday, May 8th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.05.

AIMT has been the subject of several analyst reports. Zacks Investment Research upgraded Aimmune Therapeutics from a “sell” rating to a “buy” rating and set a $21.00 target price for the company in a report on Tuesday, May 16th. ValuEngine cut Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 27th. Wedbush restated an “outperform” rating and issued a $42.00 target price on shares of Aimmune Therapeutics in a report on Monday, July 24th. Finally, Piper Jaffray Companies set a $38.00 target price on Aimmune Therapeutics and gave the company a “buy” rating in a report on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. Aimmune Therapeutics presently has an average rating of “Buy” and a consensus target price of $33.00.

Shares of Aimmune Therapeutics (AIMT) traded down 2.56% during mid-day trading on Friday, reaching $20.97. The company had a trading volume of 101,651 shares. The company’s market capitalization is $1.06 billion. Aimmune Therapeutics has a 1-year low of $12.05 and a 1-year high of $27.31. The stock’s 50-day moving average price is $20.56 and its 200 day moving average price is $19.90.

ILLEGAL ACTIVITY WARNING: This story was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.dailypolitical.com/2017/08/07/brokerages-anticipate-aimmune-therapeutics-inc-aimt-will-post-earnings-of-0-64-per-share.html.

In other Aimmune Therapeutics news, CFO Eric Bjerkholt purchased 5,000 shares of the firm’s stock in a transaction dated Friday, May 12th. The shares were acquired at an average price of $19.84 per share, with a total value of $99,200.00. Following the purchase, the chief financial officer now directly owns 5,000 shares in the company, valued at approximately $99,200. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Stephen George Dilly sold 49,400 shares of the company’s stock in a transaction on Friday, June 23rd. The shares were sold at an average price of $20.21, for a total value of $998,374.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 189,070 shares of company stock valued at $3,954,182. 24.56% of the stock is owned by company insiders.

Institutional investors have recently made changes to their positions in the stock. State Street Corp raised its position in shares of Aimmune Therapeutics by 50.5% in the fourth quarter. State Street Corp now owns 576,147 shares of the biotechnology company’s stock valued at $11,782,000 after buying an additional 193,272 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Aimmune Therapeutics during the fourth quarter valued at approximately $2,100,000. Norges Bank acquired a new position in shares of Aimmune Therapeutics during the fourth quarter valued at approximately $1,258,000. Teachers Advisors LLC raised its position in shares of Aimmune Therapeutics by 2.4% in the fourth quarter. Teachers Advisors LLC now owns 43,229 shares of the biotechnology company’s stock valued at $884,000 after buying an additional 1,025 shares during the period. Finally, Franklin Street Advisors Inc. NC acquired a new position in shares of Aimmune Therapeutics during the first quarter valued at approximately $450,000. 69.51% of the stock is currently owned by institutional investors and hedge funds.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Get a free copy of the Zacks research report on Aimmune Therapeutics (AIMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.